[New development in bisphosphonate treatment. Bisphosphonates and gastrointestinal adverse effects].
Endoscopic examination suggested gastric mucosal damage by NSAID is more serious than that of bisphosphonates. In addition, the incidence of GI-adverse effects (AEs) is reported to be insignificant, if the incidence is adjusted by history of peptic ulcer, drugs for comorbidity, sex, age and/or ways of evaluation of the AEs. The anxiety for taking medication under empty stomach may contribute to the increase of GI-AEs. Some consideration must be taken for patients with past history of peptic ulcer, and/or drug user such as NSAIDs.
Miki
Takami
T
Osaka City University Medical School, Post Graduate School of Medicine, Geriatric Medicine, Japan.
Masaki
Hideki
H
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015232:Dinoprostone / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005346:Fibroblast Growth Factors / Q000378:metabolism; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors; D015232:Dinoprostone